Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.45 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | GALR1 | P47211 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 5/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101250 | 0.89 | MET (0.46) | METAXLKDRMERTK | |
| SCHEMBL3095300 | 0.83 | AXL (0.53) | METAXLTYRO3MERTK | |
| SCHEMBL3099944 | 0.81 | AXL (0.51) | METAXLTYRO3MERTK | |
| SCHEMBL3097478 | 0.81 | KDM1A (0.41) | GALR2GALR1TLR9LMNAMAPT | |
| SCHEMBL4864644 | 0.79 | TLR9 (0.40) | GALR2GALR1TLR9LMNAMAPT | |
| SCHEMBL3101774 | 0.79 | AXL (0.52) | METAXLTYRO3MERTK | |
| SCHEMBL3108841 | 0.78 | GALR2 (0.44) | GALR2GALR1TLR9LMNAMAPT | |
| SCHEMBL3104234 | 0.77 | AXL (0.51) | METAXLTYRO3MERTK | |
| SCHEMBL3108033 | 0.76 | AOC3 (0.38) | GALR2GALR1AXLMERTKTLR9 | |
| SCHEMBL3113794 | 0.75 | AXL (0.50) | METAXLTYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | MET 357/4885GALR2 964/4885GALR1 848/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | MET 357/4885GALR2 964/4885GALR1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.